Lithium Toxicity
Critical Alerts
- Chronic toxicity is more dangerous than acute overdose at same serum level
- Neurological symptoms are the hallmark of severe toxicity
- Hemodialysis is the definitive treatment for severe toxicity
- Rebound phenomenon occurs - repeat dialysis often needed
- Watch for nephrogenic diabetes insipidus - common complication
Key Diagnostics
- Serum lithium level (therapeutic 0.6-1.2 mEq/L)
- BMP (sodium, creatinine - critical for context)
- Serial lithium levels (every 2-4 hours until declining)
- ECG (conduction abnormalities)
- TSH (chronic effects)
Emergency Treatments
- IV fluids: Normal saline for volume depletion
- Avoid NSAIDs, ACE inhibitors, thiazides: Increase lithium levels
- Whole bowel irrigation: For sustained-release formulations
- Hemodialysis: Severe neurological symptoms, level >4 mEq/L
- Supportive care: Airway protection if needed
Lithium toxicity is a potentially life-threatening condition resulting from elevated lithium levels, either from acute ingestion or chronic accumulation. Lithium has a narrow therapeutic index, making toxicity relatively common among patients on chronic therapy.
Types of Lithium Toxicity
| Type | Description | Key Features |
|---|---|---|
| Acute | Single large ingestion | GI symptoms early, neuro later; higher levels tolerated |
| Acute-on-chronic | Acute ingestion on chronic therapy | Intermediate severity |
| Chronic | Gradual accumulation on therapy | More severe at lower levels; insidious onset |
Therapeutic vs Toxic Levels
| Level (mEq/L) | Interpretation |
|---|---|
| 0.6-1.2 | Therapeutic range |
| 1.5-2.5 | Mild-moderate toxicity |
| 2.5-3.5 | Moderate-severe toxicity |
| >.5 | Severe toxicity (life-threatening) |
Important: Clinical status matters more than level alone, especially in chronic toxicity
Epidemiology
- Prevalence of toxicity: 25% of lithium-treated patients experience toxicity
- Common triggers: Dehydration, drug interactions, renal impairment
- Mortality: <1% with appropriate treatment
Pharmacokinetics
| Parameter | Value |
|---|---|
| Absorption | Complete; peak 1-2 hours (immediate-release), 4-6 hours (sustained-release) |
| Distribution | Total body water; concentrates in CNS over time |
| Protein binding | None |
| Metabolism | None (excreted unchanged) |
| Elimination | Renal (95%); half-life 18-36 hours; prolonged in toxicity |
Mechanism of Toxicity
Cellular Effects
- Competes with sodium, potassium, magnesium, calcium
- Inhibits adenylyl cyclase (reduces cAMP)
- Affects inositol phosphate signaling
- Alters neurotransmitter release
- Disrupts thyroid and renal function
Why Chronic Toxicity Is Worse
- Time for tissue distribution (especially CNS)
- At steady state, tissues equilibrated with plasma
- Lower plasma levels still reflect high tissue levels
- Acute overdose: high plasma, low tissue initially
Factors Precipitating Toxicity
| Factor | Mechanism |
|---|---|
| Dehydration | Reduced renal clearance |
| Sodium depletion | Increased renal lithium reabsorption |
| NSAIDs | Reduce GFR, increase lithium reabsorption |
| ACE inhibitors/ARBs | Reduce GFR |
| Thiazide diuretics | Increase lithium reabsorption |
| Loop diuretics | Less effect, but volume depletion matters |
| Acute kidney injury | Reduced elimination |
| Infection/fever | Dehydration |
| Heart failure | Reduced renal perfusion |
Symptoms by System
Gastrointestinal (Early, Especially Acute)
Neurological (Hallmark of Toxicity)
| Severity | Symptoms |
|---|---|
| Mild | Tremor (fine), lethargy, weakness |
| Moderate | Coarse tremor, ataxia, slurred speech, confusion, fasciculations |
| Severe | Coma, seizures, myoclonus, choreoathetosis |
Cardiovascular
Renal
Endocrine
Clinical Grading
| Grade | Features |
|---|---|
| Mild | Tremor, GI symptoms, mild lethargy |
| Moderate | Confusion, ataxia, dysarthria, fasciculations |
| Severe | Coma, seizures, cardiovascular instability |
SILENT Mnemonic for Chronic Toxicity
Critical Findings
| Red Flag | Concern | Action |
|---|---|---|
| Altered mental status | Severe CNS toxicity | ICU, hemodialysis |
| Seizures | Severe toxicity | Benzodiazepines, hemodialysis |
| Level > mEq/L | Life-threatening | Emergent hemodialysis |
| Chronic toxicity with level >.5 | Established tissue distribution | Hemodialysis |
| Hemodynamic instability | Cardiovascular toxicity | ICU, supportive care |
| Rising lithium level | Ongoing absorption | Extended WBI |
| Irreversible neurological damage | SILENT syndrome | May persist despite treatment |
SILENT Syndrome
Syndrome of Irreversible Lithium-Effectuated Neurotoxicity
- Persistent cerebellar dysfunction
- Cognitive impairment
- Basal ganglia dysfunction
- May occur despite appropriate treatment
- More common with delayed treatment or chronic toxicity
Conditions Mimicking Lithium Toxicity
| Condition | Distinguishing Features |
|---|---|
| Serotonin syndrome | Hyperthermia, hyperreflexia, medication history |
| NMS | Rigidity, hyperthermia, antipsychotic use |
| Thyroid storm | Hyperthyroidism, fever, tachycardia |
| Encephalitis | Fever, CSF abnormalities |
| Stroke | Focal neurological findings, imaging |
| Metabolic encephalopathy | Electrolyte abnormalities, liver/renal failure |
| Other drug toxicity | Specific levels, toxidrome |
Causes of Tremor in Psychiatric Patients
- Lithium therapeutic effect (fine tremor)
- Lithium toxicity (coarse tremor)
- Antipsychotic-induced parkinsonism
- Valproate tremor
- Essential tremor
- Caffeine/stimulant use
Initial Assessment
Key History
- Lithium dose and formulation (immediate vs sustained-release)
- Time since last dose or overdose
- Acute vs chronic ingestion
- Recent changes in medications
- Dehydration, illness, sodium intake
- Symptoms and timeline
Laboratory Studies
| Test | Purpose | Critical Values |
|---|---|---|
| Serum lithium | Diagnosis | >1.5 concerning; > severe |
| BMP | Sodium, renal function | Hyponatremia, elevated Cr |
| Calcium | May be affected | |
| TSH | Hypothyroidism | |
| ECG | Conduction abnormalities | T-wave changes, QT prolongation |
| Urinalysis | Urine output, concentration | Dilute in DI |
Serial Lithium Levels
Essential for Management
- Draw every 2-4 hours
- Continue until clearly declining
- Sustained-release: Peak may be delayed 12+ hours
- Post-dialysis: Recheck at 6 hours (rebound)
Level Interpretation
| Scenario | Level | Implication |
|---|---|---|
| Acute OD, asymptomatic | 2.5 | May observe with hydration |
| Chronic, mild symptoms | 1.5-2.0 | May be significant; treat |
| Chronic, severe symptoms | 2.5 | Hemodialysis indicated |
| Any, altered mental status | Any elevated | Hemodialysis indicated |
Initial Management
Volume Resuscitation
Normal saline bolus then maintenance
- Restores renal perfusion
- Enhances lithium clearance
- Corrects sodium depletion
Avoid:
- Sodium bicarbonate (no benefit)
- Forced diuresis with diuretics (no benefit, may harm)
GI Decontamination
Activated Charcoal
- Does NOT bind lithium
- Not recommended for isolated lithium ingestion
Whole Bowel Irrigation
Indication: Sustained-release lithium, significant ingestion
Solution: Polyethylene glycol electrolyte solution
Rate: 1-2 L/hour via NG until effluent clear
Contraindications: Ileus, obstruction, altered mental status without airway protection
Enhanced Elimination
Hemodialysis (Definitive Treatment)
| Indication | Details |
|---|---|
| Level > mEq/L | Regardless of symptoms |
| Severe symptoms | Seizures, altered consciousness |
| Chronic toxicity with level >.5 and symptoms | Tissue distribution established |
| Impaired renal function | Unable to clear lithium |
| Symptoms not improving with supportive care | Clinical deterioration |
Hemodialysis Parameters
Modality: Intermittent HD preferred (more efficient)
Duration: 4-6 hours typically
Expect: Rapid level decline during HD
Watch for: Rebound (levels rise 6+ hours post-HD)
Repeat HD: Often needed for rebound
CRRT: Use if hemodynamically unstable
Post-Dialysis Monitoring
- Recheck lithium level 6 hours post-HD
- Repeat HD if level rebounds >3 or symptoms return
- May need multiple sessions
Supportive Care
| Issue | Management |
|---|---|
| Seizures | Benzodiazepines |
| Airway protection | Intubation if GCS impaired |
| Hypotension | IV fluids, vasopressors rarely needed |
| Nephrogenic DI | Free water access, may need desmopressin |
| Hypothyroidism | Check TSH, treat if indicated |
Stop Offending Medications
Discontinue or Avoid
- NSAIDs
- ACE inhibitors/ARBs
- Thiazide diuretics
- Any cause of dehydration
ICU Admission Criteria
- Altered mental status
- Seizures
- Severe toxicity requiring hemodialysis
- Hemodynamic instability
- Need for airway protection
Monitored Bed Admission
- Moderate toxicity with neurological symptoms
- Elevated level requiring serial monitoring
- Unclear whether acute or chronic
Observation
- Acute ingestion, asymptomatic, mildly elevated level
- Normal renal function
- Access to serial levels
Discharge Criteria
- Asymptomatic
- Lithium level declining and <1.5 mEq/L
- Stable renal function
- Cause of toxicity identified and addressed
- Psychiatric assessment if intentional
- Follow-up arranged for lithium level and clinical status
Understanding Lithium
- Lithium is an effective medication for bipolar disorder
- It has a very narrow safety margin
- Many factors can affect lithium levels
- Regular blood monitoring is essential
Preventing Future Toxicity
Medication Safety
- Take lithium exactly as prescribed
- Do not change dose without physician guidance
- Maintain consistent salt and fluid intake
- Avoid dehydration (illness, exercise, hot weather)
Drug Interactions to Avoid
- NSAIDs (ibuprofen, naproxen)
- Do not start new medications without checking with physician/pharmacist
Warning Signs
- Increased thirst or urination
- Tremor worsening
- Nausea, vomiting, diarrhea
- Confusion, slurred speech
- Muscle weakness
Regular Monitoring
- Lithium levels as directed
- Kidney function tests
- Thyroid function tests
Elderly Patients
- More susceptible to toxicity
- Reduced renal function with age
- More sensitive to neurological effects
- Start at lower doses
- More likely to have drug interactions
Pregnancy
- Lithium associated with cardiac malformations (Ebstein's anomaly)
- Continue only if benefits outweigh risks
- Switch to alternative if possible in first trimester
- Levels decrease during pregnancy; increase postpartum
- Hemodialysis safe in pregnancy if indicated
Renal Impairment
- Reduced lithium clearance
- Requires dose adjustment
- More frequent monitoring
- Lower threshold for toxicity
- May need chronic renal replacement if caused by lithium
Intentional Overdose
- Psychiatric evaluation required
- May have additional ingestions
- Thorough toxicological workup
- Suicide risk assessment
Performance Indicators
| Metric | Target |
|---|---|
| Serum lithium level obtained | 100% |
| BMP obtained | 100% |
| Serial lithium levels ordered | 100% of significant elevations |
| Hemodialysis initiated if indicated | Within 4-6 hours |
| Nephrology consultation for HD criteria | 100% |
| Psychiatric consultation (intentional) | 100% |
Documentation Requirements
- Type of exposure (acute, chronic, acute-on-chronic)
- Formulation (immediate vs sustained-release)
- Time of ingestion
- Serial lithium levels with times
- Clinical status at each level
- Treatment provided
- Dialysis details if performed
- Disposition rationale
Diagnostic Pearls
- Chronic toxicity is more dangerous at same serum level
- Neurological exam is critical - level alone doesn't predict severity
- Sustained-release peaks late - repeat levels beyond 12 hours
- Look for the precipitant - dehydration, drugs, renal impairment
- Expect rebound after hemodialysis - recheck at 6 hours
Treatment Pearls
- Charcoal does not bind lithium - don't use it
- WBI for sustained-release - may have ongoing absorption
- Normal saline first - restore volume and sodium
- Hemodialysis is definitive for severe toxicity
- Multiple dialysis sessions often needed
Disposition Pearls
- ICU for any significant neurological symptoms
- Serial levels until declining - don't d/c on single level
- Address the cause - change meds, patient education
- Psychiatric consult if intentional overdose
- Close follow-up - reinitiate lithium carefully if needed
- Decker BS, et al. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol. 2015;10(5):875-887.
- Baird-Gunning J, et al. Lithium poisoning. J Intensive Care Med. 2017;32(4):249-263.
- Timmer RT, Sands JM. Lithium intoxication. J Am Soc Nephrol. 1999;10(3):666-674.
- Ott M, et al. Lithium intoxication: Incidence, clinical course and renal function. BMC Psychiatry. 2016;16:60.
- Adityanjee, Munshi KR, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol. 2005;28(1):38-49.
- Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. 2016;4(1):27.
| Version | Date | Changes |
|---|---|---|
| 1.0 | 2025-01-15 | Initial comprehensive version with 14-section template |